Orlando, FL Clinical Trials Report — June 2026

June 2026 brings important updates for Orlando, FL residents interested in contributing to medical research. For those considering participation, a number of trials are nearing their enrollment deadlines, making prompt action essential. Simultaneously, new opportunities have emerged, expanding the city's robust research landscape.

A total of 46 clinical trials in Orlando are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 10 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

New Research Opportunities in Orlando

This month, Orlando, FL saw the opening of 16 new clinical trials, an increase from the 12 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Orlando, FL, to 696 across 350 research facilities, highlighting the city's active role in medical innovation.

June brings several high-profile new trials to Orlando, FL, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• AstraZeneca is sponsoring two notable Phase 3 studies for Type 2 Diabetes Mellitus. The first, NCT07662135, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin," aims for 900 participants. This study will evaluate the efficacy, safety, and tolerability of elecoglipron in adults with Type 2 Diabetes Mellitus and impaired renal function who are also on dapagliflozin.
• The second AstraZeneca study, NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus," seeks 800 participants. It will assess elecoglipron alone or with dapagliflozin in adults with Type 2 Diabetes Mellitus inadequately managed with lifestyle changes or other glucose-lowering treatments.
• Novo Nordisk A/S is sponsoring NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This Phase 3 study, aiming for 650 participants, will determine if zenagamtide is safe and effective for treating excess body weight compared to semaglutide.
• Tonix Pharmaceuticals, Inc. is leading NCT07621237, "A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)." This Phase 2 trial, with 360 participants, aims to learn if TNX-102 SL effectively treats moderate to severe major depressive disorder in adults and to assess its safety.
• Evommune, Inc. is sponsoring NCT07616128, "Study of EVO756 in Adults With Migraine." This Phase 2 study will evaluate the efficacy and safety of EVO756 against placebo in 330 adults with migraine.
• A diagnostic test trial, NCT07623902, "Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population," sponsored by Jubaan Ltd., is seeking 1,436 participants. This study aims to determine if the Gixam device can effectively identify pre-cancer or cancer in the colon and rectum in average-risk adults aged 45-84 who have received a negative Fecal Immunochemical Test (FIT) result.

New trials this month in Orlando are exploring a range of conditions, with the most frequent being Type 2 Diabetes Mellitus (2 trials) and Breast Cancer (2 trials). Other conditions include Colorectal Cancer Screening (1), Crohn's Disease (1), Depression (1), Fibromyalgia (1), and Heart Health Markers (1). Drug trials account for the largest share of new studies, with 11 new drug trials, followed by 2 behavioral studies, 2 other types, 1 device trial, 1 diagnostic test, and 1 procedure trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research in Orlando. A total of 3 of the 16 new trials launched this month are actively seeking healthy volunteers. Across Orlando, FL, a total of 69 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Orlando's Leading Research Facilities

Orlando is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• AdventHealth Orlando (58 trials)
• Arnold Palmer Hospital for Children (37 trials)
• Nemours Children's Hospital (36 trials)
• Orlando Health Cancer Institute (35 trials)
• Orlando Health (32 trials)
• University of Central Florida (27 trials)
• Research Site (25 trials)
• AdventHealth (25 trials)
• Advent Health (17 trials)
• Orlando Clinical Research Center (17 trials)
• Florida Cancer Specialists (12 trials)
• Advent Health Orlando (11 trials)

These institutions offer a broad spectrum of research, from pediatric care at Arnold Palmer Hospital for Children and Nemours Children's Hospital, to oncology at Orlando Health Cancer Institute and Florida Cancer Specialists, and general medical research across the AdventHealth and Orlando Health networks.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research in Orlando. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast Cancer (4 trials)
• Hepatic Impairment (3 trials)
• Major Depressive Disorder (3 trials)
• Prostate Cancer (2 trials)
• COPD (2 trials)
• Advanced Breast Cancer (2 trials)
• Colorectal Cancer (2 trials)
• Autism Spectrum Disorder (1 trial)
• Breast Cancer Diagnosis (1 trial)

Broadening Your Search: Nearby Options

While Orlando offers a significant array of clinical trial opportunities, individuals may also find options in nearby communities within Florida. Cities with active trials include Miami (24 trials), Jacksonville (17 trials), Tampa (13 trials), Maitland (8 trials), Ocala (7 trials), Leesburg (6 trials), Ocoee (5 trials), and Hollywood (5 trials).

Participation in clinical trials in Orlando is open to a diverse range of individuals. Of the 16 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, and 1 is female-only. Industry sponsors are driving a significant portion of new research in Orlando, with 12 new industry-sponsored trials this month. Notable sponsors include AstraZeneca (2 trials), University of Central Florida (2 trials), Evommune, Inc. (1 trial), AbbVie (1 trial), and Jubaan Ltd. (1 trial).

As we move through June, Orlando's vibrant research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.